17-07-2025
Kratom Consumer Advisory Council (KCAC) Releases White Paper Debunking Claims on Safety of '7' Products
New analysis calls out misinformation, urges public health protections from dangerous 7-hydroxymitragynine (7-OH) formulations
Kratom Consumer Advisory Council (KCAC) today released a comprehensive white paper challenging recent claims that products containing isolated 7-hydroxymitragynine (also known as '7') are safe for widespread, uncontrolled consumer use. The white paper, " Have '7' Products with 7-Hydroxymitragynine (7-OH) Been Proven to Be Safe? " directly refutes assertions made in a July 7 press release by the Holistic Alternative Recovery Trust (HART), which KCAC says misrepresented findings from a report HART itself commissioned from healthcare consulting firm Marwood Group.
KCAC Chair Dr. C. Michael White, Pharm.D., FCP, FCCP, FASHP, and Distinguished Professor of Pharmacy Practice at the University of Connecticut, issued a stark warning:
'It is dangerously misleading to suggest that 7 products are safe for public sale without medical oversight. Marwood Group's own report, despite being commissioned by HART, clearly concludes that synthetic 7-hydroxymitragynine is a potent opioid agonist with high abuse potential, rapid tolerance development, and physical dependence in animal models. HART's attempt to erase key parts of the report after publication, including these risk statements, is an alarming act of public deception that endangers consumers.'
The KCAC white paper cites the following key concerns from the Marwood Group report that HART initially published and then quietly removed:
The KCAC paper refutes Marwood Group's assertion that 7-hydroxymitragynine has a lower risk of respiratory depression. They used a surrogate marker called beta-arrestin recruitment to say the risk was lower without looking at actual animal studies where breathing was assessed and shown to be depressed, just like with morphine. It also provides a balanced perspective on anecdotal experiences with 7 products where consumers report widespread recreational use for euphoria and suffering from severe addiction.
'We've seen this playbook before, downplaying the risks of potent opioids while encouraging unregulated use. The opioid crisis of the 2000s began with similar false assurances,' said Dr. White. 'We must not repeat history with synthetic 7-hydroxymitragynine. These products must be evaluated through rigorous clinical trials and carefully controlled, not sold like candy at gas stations.'
The white paper also highlights KCAC's support for the FDA's July 15 warning letters against firms illegally marketing synthetic 7-hydroxymitragynine products and making unsubstantiated medical claims.
KCAC calls on regulators, lawmakers, and the media to take a clear-eyed view of the risks posed by synthetic 7-hydroxymitragynine products and urges a halt to the sale of these potent synthetic derivatives outside of clinical or research settings.
The full white paper, 'Have '7' Products with 7-Hydroxymitragynine (7-OH) Been Proven to Be Safe?' is available here.
About Kratom Consumer Advisory Council (KCAC)
Kratom Consumer Advisory Council (KCAC) is an independent board made up of a clinician-scientist and consumers that uses the strongest available evidence to produce position statements that promote evidence-based policy. The KCAC is supported by the Global Kratom Coalition which advocates for regulations that protect consumers and curbs the sale of adulterated or synthetic products falsely marketed as kratom. For more information, visit
Media Contact
Dr. C. Michael White
[email protected]
###
SOURCE: Kratom Consumer Advisory Council (KCAC)
Copyright 2025 EZ Newswire
